Search Results

prioritized because they fit a clean story, not because they meaningfully reduce scientific or commercial risk Not because risk disappears, but because decisions remain grounded in a framework that fundraising cannot

Not from polished plans—but from patterns of curiosity, risk-taking, and mentorship loops.

interpretation doesn’t just waste time; it costs viable compounds, credibility, and millions in development risk

As Kenakin explains, all GPCR signaling is allosteric , and pretending otherwise introduces risk at every

get a framework to predict duration, penetration, and PK/PD separation—so decisions move faster and risks

helped shape products used across biotech and academia—and why play, failure, and surprise are not risks

Celtarys Research – Optimizing HTRF with Fluorescent Ligands Traditional ligand-binding approaches risk

Assumptions and Opportunities High-throughput PK panels have transformed discovery, but they introduce new risks

Drug Discovery: Your Edge If you’re still making calls by sight, habit, or tradition, you’re leaving risk

In life and career, taking risks can lead to personal and professional growth.

ligand diversity expands — including peptide agonists and biased ligands — ignoring probe dependence risks

CRO partners, and GPCR experts to help teams move faster — from idea to discovery — while reducing risk

Teams that don’t understand how to detect, interpret, and exploit these mechanisms risk walking away

inhibitors, or antagonists, you must recreate the “working system” they’ll face in vivo—otherwise you risk

biotherapeutic drug discovery Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk

They define risk. Compounds fail when assumptions about selectivity prove wrong in vivo.

Assay volume control becomes a tool for risk management, translational prediction, and mechanistic insight

relying on descriptive observations—“looks like a shift,” “seems like baseline activation”—you’re leaving risk

Additional data feels like risk reduction, even when it does not change the strategic picture.

Automates New Radioligand Therapy Production Plant Novartis’ Lutathera reduces disease progression risk

transport by CCHCR1 via direct interaction Industry News Novartis Lutathera® significantly reduced risk

a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk

This scarcity made the field both exciting and high-risk.

Separate effect size from time:  Use allosteric modulators to expand therapeutic index and reduce overdose risk

One more experiment to reduce risk. One more indication to keep options open.

provide an additional check against off-target cytotoxicity or morphological changes, reducing the risk